Abstract | BACKGROUND: The clinical effectiveness of amiodarone must be weighed against the likelihood of adverse effects. Adverse effects are less common in children than in adults, yet there have been no large studies assessing the efficacy and safety of amiodarone in the first 9 months of life. We sought to assess the safety and efficacy of amiodarone as primary therapy for supraventricular tachycardia in infancy. METHODS: RESULTS: Rhythm control was achieved in all patients. Of the 34 patients who have reached 1 year of age, 23 (68%) have remained free of arrhythmia, despite discontinuation of propranolol and amiodarone. Growth and development remained normal for age. Higher loading doses of amiodarone were associated with an increase in the corrected QT interval, but no proarrhythmia was seen. There were no side effects necessitating drug withdrawal. CONCLUSIONS:
|
Authors | S P Etheridge, J E Craig, S J Compton |
Journal | American heart journal
(Am Heart J)
Vol. 141
Issue 1
Pg. 105-10
(Jan 2001)
ISSN: 0002-8703 [Print] United States |
PMID | 11136494
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Anti-Arrhythmia Agents
- Amiodarone
|
Topics |
- Amiodarone
(therapeutic use)
- Anti-Arrhythmia Agents
(therapeutic use)
- Female
- Follow-Up Studies
- Humans
- Infant
- Infant, Newborn
- Male
- Tachycardia, Supraventricular
(drug therapy)
|